These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21929691)

  • 1. Factor VIII inhibitors in previously treated hemophilic patients.
    Mannucci PM
    J Thromb Haemost; 2011 Nov; 9(11):2328-9. PubMed ID: 21929691
    [No Abstract]   [Full Text] [Related]  

  • 2. Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII.
    Aledort LM; Navickis RJ; Wilkes MM
    J Thromb Haemost; 2011 Nov; 9(11):2325-7. PubMed ID: 21880112
    [No Abstract]   [Full Text] [Related]  

  • 3. Concentrate-related inhibitor risk: is a difference always real?
    Iorio A; Marcucci M; Makris M
    J Thromb Haemost; 2011 Nov; 9(11):2176-9. PubMed ID: 21854537
    [No Abstract]   [Full Text] [Related]  

  • 4. Searching for the role of primary prophylaxis in preventing inhibitor development in hemophilia A.
    Coppola A; Tagliaferri A; Franchini M
    J Thromb Haemost; 2012 Sep; 10(9):1954-60. PubMed ID: 22758924
    [No Abstract]   [Full Text] [Related]  

  • 5. Haemophilia A and inhibitors: advances in prevention and ITI treatment optimization.
    Kruse-Jarres R
    Haemophilia; 2014 Sep; 20 Suppl 6():1. PubMed ID: 24975699
    [No Abstract]   [Full Text] [Related]  

  • 6. Exposure to factor VIII and prediction of inhibitor development: exposure days vs. danger days, or both?
    Hermans C; Astermark J; De Moerloose P
    J Thromb Haemost; 2012 Oct; 10(10):2194-6. PubMed ID: 22846047
    [No Abstract]   [Full Text] [Related]  

  • 7. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates.
    Kempton CL; Soucie JM; Abshire TC
    J Thromb Haemost; 2006 Dec; 4(12):2576-81. PubMed ID: 17002659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A continuing challenge: treatment of hemophilic children with acquired factor VIII inhibitors.
    Bell BA
    Am J Pediatr Hematol Oncol; 1993 Feb; 15(1):105-6. PubMed ID: 8447549
    [No Abstract]   [Full Text] [Related]  

  • 9. Postpartum acquired factor VIII inhibitors.
    Franchini M
    Am J Hematol; 2006 Oct; 81(10):768-73. PubMed ID: 16868941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks of inhibitors from recombinant factor VIII: a quarter of a century to reach the conclusion.
    Burnouf T; Strengers PF
    J Thromb Haemost; 2016 Oct; 14(10):2073-2074. PubMed ID: 27496669
    [No Abstract]   [Full Text] [Related]  

  • 11. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
    Kessler CM; Ludlam CA
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence for antiphospholipid antibodies in hemophilic children with factor VIII inhibitors. Recombinate PUP Study Group.
    Nuss R; Jacobson L; Hathaway WE; Manco-Johnson M
    Thromb Haemost; 1999 Nov; 82(5):1559-60. PubMed ID: 10595659
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.
    Lapalud P; Rothschild C; Mathieu-Dupas E; Balicchi J; Gruel Y; Laune D; Molina F; Schved JF; Granier C; Lavigne-Lissalde G
    J Thromb Haemost; 2015 Apr; 13(4):540-7. PubMed ID: 25603934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I treat inhibitors in haemophilia.
    Makris M; Hay CR; Gringeri A; D'Oiron R
    Haemophilia; 2012 Jul; 18 Suppl 4():48-53. PubMed ID: 22726083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The literature on inhibitors: articles that influence my management of patients with hemophilia A and high-titer inhibitors.
    Leissinger CA
    Am J Hematol; 2012 May; 87 Suppl 1():S23-6. PubMed ID: 22473571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment with rituximab in an elderly patient with acquired factor VIII inhibitor.
    Cretel E; Jean R; Chiche L; Durand JM
    Geriatr Gerontol Int; 2009 Jun; 9(2):197-9. PubMed ID: 19490140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A.
    Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP
    Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporarily successful eradication therapy in acquired haemophilia with high inhibitor titer: a case report with a new protocol.
    Ilonczai P; Schlammadinger A; Oláh Z; Rázsó K; Bereczky Z; Boda Z
    Thromb Haemost; 2008 Jul; 100(1):149-50. PubMed ID: 18612550
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.